Capricor says its cell therapy improved heart and muscle function in Duchenne patients

Taking stock of the drug industry, from the lab to the medicine chest

December 3, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Capricor says its cell therapy improved heart and muscle function in Duchenne patients The outcome in the latest Phase 3 study will likely bolster the treatment's regulatory future with the Food and Drug Administration. By Adam Feuerstein and Jason Mast STAT+ | Aging startup backed by Sam Altman chases $5 billion valuation The longevity startup backed by OpenAI CEO Sam Altman is close to raising what could be one of the drug industry's largest investment rounds By Allison DeAngelis STAT+ | FDA removes longtime over-the-counter drugs regulator from her position The move comes a day after Richard Pazdur, a top FDA official and Michele's boss, announced his decision to retire. By Lizzy Lawrence Adobe STAT+ | Bristol to enroll more patients in key study of Cobenfy in Alzheimer's psychosis The company is hoping to expand its drug Cobenfy into additional neuropsychiatric indications beyond schizophrenia. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser